Background: Adipose tissue, which can be readily harvested via a number of liposuction techniques, offers an easily accessible and abundant source of adipose-derived stem cells (ASCs). Consequently, ASCs have become an increasingly popular reconstructive option and a novel means of aesthetic soft tissue augmentation. Objectives: This paper examines recent advances in the aesthetic surgery field, extending beyond traditional review formats to incorporate a comprehensive analysis of current clinical trials, adoption status, and the commercialization pathway. Methods: Keyword searches were carried out on clinical trial databases to search for trials using ASCs for aesthetic indications. An intellectual property landscape was created using commercial software (Thomson Reuters Thomson Innovation, New York, NY). Analysis of who is claiming what in respect of ASC use in aesthetic surgery for commercial purposes was analyzed by reviewing the patent landscape in relation to these techniques. Key international regulatory guidelines were also summarized.
Adipose-derived stem cells (ASCs) are progenitor cells that can be isolated from the stromal vascular faction (SVF) component of lipoaspirate. They are of mesenchymal origin 1 and are considered multipotent due to their ability to differentiate into a range of adult cell types including adipocytes, osteoblasts, myocytes, and neurons. 2 This offers considerable application within medical and surgical fields for a variety of indications that employ both tissue engineering and regenerative medicine principles for clinical application. [3] [4] [5] Due to the relatively abundant supply of these cells and the ability to harvest them through standard liposuction techniques, 6, 7 ASCs have become an increasingly popular resource for tissue engineering and, in particular, offer a novel means of aesthetic soft tissue augmentation. 8 This has subsequently led to refinement of conventional autologous fat transfer, whereby fat is harvested from one anatomical region and transferred to another more aesthetically desirable one. Originally described in 1983, 9 the procedure has been subject to numerous modifications and is employed by a number of plastic surgeons for indications such as breast, 10 buttock, 11 and facial augmentation. 12 Although cell assisted lipotransfer (CAL) will not replace implants or reconstructive procedures (due to the shape and projection profiles they are able to achieve in the breast, for example), it has the potential to serve as an adjunct for small corrections or volume increases, and may serve as a less invasive option for patients hoping to achieve subtle aesthetic enhancements or facial augmentation.
With a demonstrable safety profile, reported graft retention in conventional fat transfer varies from 55% to 82%, so the efficacy has the potential to be improved. [13] [14] [15] This resorbtion is thought to result from poor graft vascularization and consequent necrosis of a large proportion of the transplanted fat. 4 The challenges surrounding poor graft vascularization and necrosis have been somewhat mitigated through "cell-assisted" lipotransfer techniques. In this procedure, autologous fat grafts are enriched with SVFs containing much higher progenitor cell numbers. SVF is the portion of fat abundant with progenitor cells including ASCs and preadipocytes, which are thought to enhance graft viability and improve long-term outcomes. 14 Although fat in conventional autologous transfer is rich in SVF and progenitor cells, it is at insufficient levels to cause desirable effects. The explanation for this is that most of the progenitor cells lie in close proximity to adipose vasculature, which is disrupted when liposuction occurs. Additionally, a substantial number of these cells remain in the fluid portion of the harvested fat that is not utilized in grafting. 4, 16 To overcome this, a portion of aspirated fat is used to isolate and concentrate the SVF and formulate a graft containing high stem cell populations ( Figure 1 ).
Although a promising technique, there are a number of significant translational barriers impeding development of these technologies. 17, 18 CAL is impeded by barriers affecting the entire field of stem cell therapeutics, including a lack of regulation relating to cell therapy safety and efficacy, and a poor understanding of long-term outcomes of such therapeutics. 19 However, a number of barriers are specifically applicable to aesthetic surgery-for example stem cell tourism or the ethical considerations applying to nontherapeutic research. This paper examines recent advances in the field and goes beyond traditional review formats by offering comprehensive analyses of current clinical studies, clinical adoption, and commercialization. The latter is achieved through an advanced technical collation of the current global clinical trial and intellectual property landscapes related to these procedures to provide a holistic glimpse at the clinical and commercial aspects of ASCs and their role as powerful cellular therapies in cutting-edge aesthetic applications. To date, no review has analyzed the commercial landscape employing a quantitative metric for evaluation. Here, we present for the first time the global patent landscape for the use of ASCs in aesthetic surgical procedures and examine its implications for the commercialization of these platform technologies. Ultimately, we identify and discuss translational barriers to the clinical adoption of these aesthetic procedures.
METHODS
The search carried for clinical trials relating to CAL and aesthetic indications was conducted and reported according to the PRISMA guidelines. 20 The only inclusion criteria that was applied was that the clinical trial must apply cell assisted lipotransfer for an aesthetic indication, in part or in whole. The clinical trial landscape of CAL therapeutics was identified through targeted searches (by Z The patent search was conducted and reported according to preliminary guidelines published by our group. 21 To construct the patent landscape examining the use of adipose-derived stem cells in aesthetic surgery, patent applications from 2002 to present (January 2017) were harvested using Thomson Innovation competitive intelligence software. In order to identify relative patent records, keyword searches were performed on the title, abstract, and claims sections of a patent. Both granted patents and published patent applications were searched across a global dataset of over 50 patent authorities. All patents were subject to manual review: the inclusion criteria were that the claims of each patent had to involve the use of cell assisted lipotransfer for an aesthetic indication, in part or in whole (Z.A.). Patent selection was reproduced by C.H. Search terms can be found in Appendix A. Temporal, geographical, assignee, and claims analyses were then performed on the resulting patents. This information was summarized in graphical form.
RESULTS

Clinical Trial Landscape
A total of 1250 ongoing clinical trials were identified through searches of the clinical trial databases. After screening, 12 were included. The studies found through our search of key clinical trial registries are summarized in Table 1 . Inclusion and exclusion criteria applied within each trial are summarized in Table 2 .
In total, 12 clinical trials report the use of CAL for at least one cosmetic indication; half of these involved CAL in breast augmentation procedures, 3 examined CAL in facial augmentation procedures, one evaluated the use of CAL in buttock augmentation, and one further study used CAL to treat scarring. Eight of the 12 trials are based in academic centers and 4 studies are being conducted by commercial organizations: two by Biomaster Inc. (Yokohama, Japan), a Japanese company developing adipose-derived stem cell regenerative technology, and two by Antria (Greensburg, PA), an American company developing autologous adult stem cell techniques. Figure 2 demonstrates the global distribution of ongoing trials. The majority are located in the United States, with 6 ongoing trials, followed by 3 trials in Japan, and one trial in each of Denmark, China, and Pakistan.
Trial variables and control group evaluations were also carried out on the 12 studies identified through search of clinical trial databases. The results are presented in Table 1 . Control groups are lacking in current trials (Figure 3) . Five of the 12 identified studies plan to use one. In the majority of the current trials identified, a parallel assignment model is to be used in which the control group is expected to receive conventional autologous fat grafts. We also found that a large proportion of the trials are in the patient recruitment stage, which possibly indicates a difficulty in recruiting a large number of participants ( Figure 4 ). Because many of these trials are in such early phases ( Table 1 highlights that current trials are predominantly early Figure 1 . The cell-assisted lipotransfer procedure. In the cell-assisted lipotransfer procedure fat is harvested from a patient's donor site. This harvested fat is then separated with one half being used to harvest adipose-derived stem cells and the other being processed for use as a fat graft. The 2 constituents are then combined and placed within the recipient site. Note that the black arrows indicates the procedure for a conventional autologous fat transfer procedure. Adapted from Arshad et al. 19 phase-with just a single trial in phase one and the rest in phase 2) there was limited information available relating to the intended longevity of the study in terms of monitoring and long-term patient outcomes. Due to the large number of trials with an absence of follow-up data, it is unclear whether future trials will follow-up Currently taking or have taken NSAIDs within last 2 weeks or corticosteroids within the last 6 weeks prior to screening Diagnosis of any of the following medical conditions:
• Active malignancy (diagnosed within 5 years), except for treated nonmelanoma skin cancer or other noninvasive or in situ neoplasm (eg, cervical cancer) • Active infection • Type I or Type II diabetes • Skin/bone deformities in the face, including scaring or hyperpigmentation within the graft site Patients who are unlikely to comply with the protocol (eg, uncooperative attitude, inability to return for subsequent visits, dementia, and/or otherwise considered by the investigator to be unlikely to complete the study) Patients with a known drug or alcohol dependence within the past 12 months as judged by the investigator Dermal fillers or facial reconstruction within the past 24 months, subjects must also refrain from such procedures during the duration of the study. Patients with major illnesses involving the renal, hepatic, cardiovascular, and/or nervous systems. Patients with elevated kidney and/or liver functions Any other disease condition or laboratory results that in the opinion of the investigator may be clinically significant and render the subject inappropriate for the study procedure(s), may alter the accuracy of study results, or increase risk for subjects. Patients with life-expectancies less than 9 months Patients with known collagenase allergies Patients with idiopathic or drug-induced coagulopathy Pregnant females On radiotherapy or chemotherapy agents Taking strong CYP450 inhibitors Patients with a history of keloids or hypertrophic scar formations Previous treatment with any synthetic fillers in the inframalar area patients sufficiently long enough to evaluate long-term outcomes ( Figure 5 ). Further clarity is required in relation to optimum follow-up duration in order to confirm the long-term safety profile of this technique.
Patent Landscape
A total of 950 patents were identified through our search; after manual review, 115 were included in our analysis. The commercial potential for adopting ASCs in a wide range of aesthetic applications is reflected by the patenting activity in this area-companies are actively seeking to establish best practice standards in a dynamic and competitive field. Intellectual property safeguards inventions so companies may profit at the exclusion of competition (for a period of twenty years) in exchange for publishing their invention. It therefore serves as a powerful tool to incentivize research into the development of products. 22 Patenting is consequently an essential step in the commercialization of a therapeutic product or inventive technique. 23 Here, key patents that have been filed relating to CAL and aesthetic indications are examined, to inform readers of the status of CAL technologies and provide an indication of both translational stage and cosmetic market appetite. In total, we found 115 relevant patent documents from the years 2005 to 2015 (Figure 6 ), with the number of patents filed in relation to CAL and aesthetic indications significantly increasing in recent years. Supplementary Figure 1 identifies the leading innovating countries with the highest number of patents relating to the use of CAL technologies in aesthetic procedures. The United States dominates the market and is home to several companies that are developing ASC technologies, including Cytori Therapeutics Inc. (San Diego, CA), which is based in San Diego, and currently the number one patent owner (Supplementary Figure  2) . Cytori is currently focused on developing cell based therapies from adult adipose tissues and have developed the CAL-related product, Celution System (see Appendix B for case study), that processes adipose tissue to isolate and concentrate adipose-derived stem cells. 23 The Celution System has been used in several clinical trials. [24] [25] [26] Supplementary Figure 3 depicts a themescape map and provides an overview of the different aspects of CAL that have been patented. Thomson Innovation was used to electronically search through the title, abstract, claims, and uses section of each patent document to cluster patents containing key words (represented by the white dots). Related patents are grouped in contours and the more patents that are related to certain key themes, the higher the elevation of the contour. Generally, the map reveals a fragmented landscape with a number of distinct peaks highlighting the lack of overlap in CAL technologies. White peaks, areas of high activity, largely concern methods of extracting, processing, and injection of enriched fat grafts. The peak entitled "centrifuge" and "concentration" refer to patents on products used to concentrate adipose-derived stem cells from fat such as the Celution System created by Cytori Therapeutics. A number of patents have been filled 
Regulation of ASCs in the United States, European Union, and Japan
Regulation is an important consideration when discussing the translation of therapies from the "bench to bedside." Aside from dictating the use of a therapy in a particular jurisdiction, regulations ensure the clinical safety and efficacy of a product. Here, we briefly summarize penitent legislation in the regulatory jurisdictions identified as being key through our clinical trial and intellectual property landscaping searches. This section also highlights the differing regulatory definitions, and requirements, that products containing ASCs will have to navigate to be utilized on a global level.
In the United States, for example, ASCs are regulated underneath the broader category Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). HCT/ Ps are further divided as 361 or 351 products, a categorization, which determines how stringently the Food and Drug Administration (FDA) regulates their access to the market. The 351 products are regulated as a drug and therefore are subject to pharmaceutical regulations and stringent clinical trials in order to gain US market approval. In contrast, 361 products do not require market approval and must only comply with The Public Health Services Act and Current Good Tissue Practice legislations, under the Code of Federal Regulations, Title 21, Part 1271. 27 To be regulated as a 361 product, the product must be only minimally manipulated, intended for homologous use and not used in conjunction with another article. Minimal manipulation is defined by FDA guidance as: cutting; grinding; shaping; centrifugation; soaking in antibiotic solution; sterilization by ethylene oxide treatment or irradiation; cell separation; density gradient separation; lyophilization; freezing; cryopreservation; selective removal of B-cells, T-cells, malignant cells, red blood cells, or platelets. Additionally, the cell product must have no systemic effect or rely on the metabolic effect of the patients' living cells, with the exception being autologous cells, those donated from a first-or second-degree blood relative or intended for reproductive use. 28 In 2014 the FDA released the draft guidance document Human Cells, Tissues, and Cellular and TissueBased Products (HCT/Ps) from Adipose Tissue: Regulatory Considerations 29 indicating that the current FDA opinion is that adipose-derived stem cells are substantially manipulated (beyond mere isolation and purification techniques). In particular, the report stated that stromal vascular fraction is to be treated and regulated as a drug. The FDA classifies adipose tissue as a structural tissue for regulatory concerns. Therefore, the isolation of SVF via centrifugation is considered substantial manipulation, as the isolation of purified SVF alters the tissue function, regulating such therapeutics as 351 products. However, this is only a draft guidance and not a legally binding document, so at this time, the use of ASCs in a manner compliant with Section 361 still qualifies such therapies for patient use without clinical trials. 30 In the European Union (EU), such therapeutics are regulated as advanced therapy medicinal products (ATMPs). ATMPs are further divided into a gene therapy medicinal product (GTMP), somatic cell therapy medicinal product (SCTMP), tissue-engineered product (TEP), or combination product. ATMPs are subject to European Medicines Agency (EMA) regulation and require market approval. Similar to the United States, a product containing ASCs may be subject to only public health legislation if it is not substantially manipulated, is used in a homologous manner, and is not combined with another article. 31 Of particular interest is the ability of some ASC products to be regulated as 361 products in the United States or non-ATMP in the EU, therefore circumventing the market approval process. Alarmingly, this has resulted in the advent "stem cell clinics," where patients may pay significant fees to be treated with unproven stem cell therapies for a variety of indications. 32 One analysis found that 61% of these clinics used adipose-derived stem cells. Such unproved, inadequately tested treatments are often ineffective and furthermore, may significantly compromise patient safety. 33 Japan has specific regulation solely for regenerative medicine products, regulating such products separately from classical drugs and biologics, under the label "cell/tissue engineered product." Nonhomologous use or "processing" of the cells automatically delegates the product under this category. Regenerative medicines are offered special initiatives in clinical trials in order to encourage Figure 6 . The figure shows how the number of patents filed in relation to CAL and aesthetic surgery has been increasing in recent years. development of this incipient field. Consequently, such therapeutics may receive conditional market approval after demonstrating probable benefit and safety in a small sample size. During this conditional approval, data is continuously collected for reevaluation and final market approval (within 7 years).
DISCUSSION
The unique aspects of our study are the intellectual landscape, discussion of ongoing clinical trials, and discussion of regulatory guidelines as they relate to the technology. These are essential areas that will be of extensive utility to academics and industry-related workers involved in the development of CAL-related technology. CAL technology is being utilized at a number of centers globally, it remains to be seen as to whether it will be widely adopted. Extensive research and development has been invested into this area, and owing to a number of clinical trials focusing on its applications, there appears to progressive commercial interest indicated by the relatively large proportion of studies being carried out by private entities. The results of our patent landscaping analysis suggest an increasing commercial appetite for these technologies: indicated by the increasing number of published patents in recent years ( Figure  6 ). Our analysis of patented claims also indicates that the use and procedures are distinct enough that researchers are not likely to need to innovate in order to circumnavigate each other's inventive steps in using these technologies. This is indicated by the distinct white peaks in Supplementary Figure 3 .
To facilitate clinical adoption of CAL in aesthetic surgery, however, there are a number of obstacles that must be overcome aside from FDA and EU regulation that has already been discussed. Our clinical trial landscape identified 12 ongoing clinical trials using CAL for aesthetic indications. The majority (50%) used CAL for breast augmentation, with the remainder for facial/ buttock augmentation or scar indications. The commercial appetite for such technologies is exemplified by a significant increase in patents in this area, in addition to a large number of trials being organized by commercial entities rather than conventional academic centers.
Current studies are attempting to ascertain complication rates, cosmetic outcomes, and the degree of graft retention. Cosmetic outcomes have generally been assessed by patient reported outcome measures (PROMs) and/or surgeon reported outcomes, and clinical measurements of skin quality (Table 1) . Interestingly, a systematic review by Arshad et al also found that the reporting of patient reported outcomes was significantly biased as the methods and/or tools used to collect this information was not adequately described. We suggest in future investigators use validated PROMs such as BREAST-Q to allow more consistent and reproducible results. BREAST-Q also takes a holistic approach to patient satisfaction; taking into account factors such as psychosocial, physical, and sexual well being. 34 Graft retention can be measured in a number of ways extending beyond qualitative observation, making use of tissue thickness, and physical measurements. Variability in assessment methodologies makes it difficult to compare results from different studies. This is exacerbated by confounding factors in the procedure's heterogeneous study populations; characterized by differences in age, breast cancer susceptibility, nulliparity vs gravidity, breastfeeding status, and variable hormone profiles. Such factors may account for a significant variation in outcomes and it is therefore critical to appropriately define initial patient cohorts and fully delineate the potential advantages this procedure may offer.
In the past, clinical trial results have been criticized for their poor trial design for reasons including insufficient monitoring of long-term outcomes or inadequately addressed safety issues. A recent systematic review and meta-analysis by Zhou et al of cell assisted lipotransfer (CAL) for clinical indications (including cosmetic), concluded that when CAL was used for facial indications it reduced fat resorption and complications, while also decreasing the need for reoperation. 18 However, no such statistically significant advantages were found to apply to the use of CAL for breast surgery. A further systematic review by Arshad et al concluded that there was no evidence supporting the superiority of CAL over conventional autologous fat transfer techniques. It concluded that further, higher quality trials are required that employ larger sample sizes, use of statistical techniques to delineate the significance of any findings, and longer-term follow up to ascertain the full safety profile of CAL-most notably the risk of malignancy. 19 Other high level studies published in the area are concurrent with these conclusions. 35 Although the safety profile of autologous fat transfer has been demonstrated, 13, 36, 37 this is not true of CAL. More specifically, preclinical models have suggested there is an increased incidence of locally occurring malignancy and metastasis with the use of ASCs in the breast. 38 As this technique is being incorporated into cosmetic surgical procedures that already carry an inherent complication risk, it is particularly important that such techniques are carefully evaluated from a risk−benefit perspective due to the fact that such surgeries are usually not medically necessitated.
Although the majority of studies investigating CAL for aesthetic indications generally report favorable outcomes, they are largely limited by small sample sizes, short follow up, and lack of appropriate control groups. A number of current clinical trials have expressed uncertainty in the exact mechanism by which adipose stem cells exert their effect, alongside limited knowledge regarding dosages or patient populations who might most benefit. Future clinical trials should address these issues before the clinical adoption of CAL.
In our analysis of ongoing clinical trials we found five out of 12 utilizing control groups. This raises concerns with regards to methodological rigor and the ability to carry out statistically meaningful comparisons of CAL to conventional procedures. In terms of follow up, it is unclear whether ongoing clinical trials will be able to delineate long-term outcomes, in particular the risk of malignancy, as this metric was poorly reported on clinical trial databases. Adequate long-term results would require the risk of malignancy to be evaluated. Therefore, adequate follow up would be 10/20 years. In addition, future trials are expected to recruit a substantially larger number of participants, which will enhance study power.
With uncertain long-term outcomes it can be seen as unethical to be utilizing this procedure for what is a nontherapeutic indication by putting patients through unnecessary risks. Without controlled clinical trials employing long-term follow-up periods, it is not possible for patients to provide adequate informed consent. This is concerning in the sense that a number of cosmetic surgeons are advertising adipose stem cell based therapies to patients and contributing to an unregulated "stem cell tourism" industry. A study examining the claims of stem cell therapy applications in cosmetic surgery across 50 websites 38 revealed alarming results; it identified numerous false claims, including the advertisement of platelet-enriched plasma as a stem cell-based therapy 39 and adverts for "stem cell facelifts" 40 -a procedure that does not itself per se have antiaging effects but rather increases facial volume to give a rejuvenated appearance. It is important to ensure appropriate regulation of these direct-to-consumer activities and safeguard patients with accurate and ethical marketing strategies. This will help mitigate any unprecedented adverse events and potential public backlash towards what might be a promising aesthetic application. Until such issues can be overcome and clinical trials can demonstrate safe long-term outcomes, the use of such procedures should be limited to regulated and well-organized clinical trials.
Limitations
There are a number of limitations inherent to this study. Although we used broad search terms to identify pertinent patent documents and clinical trial records, it is possible that some may have been inadvertently missed. Notably, our methodology only searched four clinical trial registries, namely: the ISRCTN, clinicaltrials.com, EU Clinical Trials Registers, and the NIPH Clinical Trials Search. This represents the major databases that are available on an open access basis, but it is possible that some may not be included in either of these registries. It may also be possible that some patents were missed despite our thorough search on commercially available software.
CONCLUSIONS
The use of adipose-derived stem cells is progressing within the field of aesthetic surgery with a number of clinical phase trials already completed. Secondary analysis of these studies has found a lack of methodological rigor with regards to a lack of sufficient sample sizes and control groups, making it difficult to ascertain the statistical significance of these studies. There is also a lack of long-term follow-up data to determine long-term safety and efficacy. Our search for ongoing clinical trials identified a global effort to evaluate these therapies in the clinic with trials ongoing in Europe, North America, and Asia. Ongoing clinical trials attempt to address issues raised in the quality of completed studies with larger sample sizes. Nonetheless, it is unclear whether they will employ follow-up times that are long enough to delineate long-term efficacy and safety, as only 6 ongoing trials report this information. We would recommend that future clinical trial organizers take note of this fact to add to the clinical data that are already available concerning the use of stem cells in aesthetic surgery. Adequate long-term results would require the risk of malignancy to be evaluated. Therefore, adequate follow up would be 10/20 years. Less than half plan on using a control group. Furthermore, 115 relevant patents were also identified, with temporal analysis suggesting a rapid growth in the number of patents published in the area. This, along with the fact that 50% of trials are being carried out by commercial entities, indicates both commercial and consumer appetite, implying that there is need for novel techniques in the aesthetic surgery domain. Our analysis also highlighted gaps in innovation that could be exploited to generate intellectual property. Before the clinical adoption of such technologies can occur, there are a number of translational barriers these technologies face. These include regulatory challenges, ethical concerns, and marketing practices. Harmonizing global regulatory requirements and tightening regulation with regards to advertising through appropriate bodies will somewhat address these issues. If future clinical trial data suggest these technologies are effective and safe, this will pave the way for their use by cosmetic surgeons.
